clinical trial · NCT03264664

Study of E7386 in Participants With Selected Advanced Neoplasms

EISAI INC →·phase1·active not recruiting·n = 60

Advanced NeoplasmsE7386

brief summary

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.

started

Jul 27, 2017

primary completion

Mar 31, 2027

completion

Mar 31, 2027

last updated

Jun 8, 2026

official title

An Open-Label, Multicenter, Phase 1 Study of E7386 in Subjects With Selected Advanced Neoplasms

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol